Navigation Links
More Causes of Bladder Cancer Identified

Smoking is a well known risk factor for bladder cancer but researchers now say they have uncovered even more factors // that could lead to the disease.

For the study researchers studied 298 patients with bladder cancer and 308 people who served as controls. The participants were surveyed about their smoking habits and their exposure to other environmental factors believed to be related to bladder cancer. Blood was also collected and measured for levels of nine arylamine-hemoglobin adducts -- proteins that form in the blood after exposure to the carcinogenic compound arylamine.

Arylamine is known to exist in cigarettes, permanent hair dyes, and other environmental sources. In all but one of the nine levels measured, researchers found higher levels in smokers than in nonsmokers, and the levels of all nine adducts were higher in cancer patients than in control subjects.

While smoking continues to be the greatest risk factor for bladder cancer, researchers say many nonsmokers are also at increased risk of bladder cancer due to exposure to arylamine from other sources and they say that more study should be done to identify the other non-smoking-related sources of arylamines.
'"/>




Page: 1

Related medicine news :

1. Breast Cancer Surgery Causes Psychological problems
2. Causes of weakness in the aged
3. Gene Mutation Causes Ovarian Failure
4. Studying The Causes Of Autism
5. Heart Drug Also Effective In Preventing Specific Causes Of Death
6. The Causes Of Acid Reflux Questioned
7. Causes of drug induced liver disease
8. Junk Food Causes High Level Of Insulin Resistance In Children
9. Red Color Causes The Allergic Reaction To Strawberries
10. Studies On Hearing Loss Discovers New Causes
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: More Causes Bladder Cancer Identified

Other Medicine News:Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 2Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 3Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 4Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 5Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 6Health News:Argonne's Blue Gene/P to host large cadre of INCITE researchers 7Health News:Heart Association Renews Call for CPR Training 2Health News:Heart Association Renews Call for CPR Training 3Health News:QLT reduces workforce as first step in its strategic restructure 2Health News:QLT reduces workforce as first step in its strategic restructure 3Health News:Ad Campaign Targets Abuses by Not-For-Profits 2Health News:Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed 2Health News:Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed 3Health News:Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed 4Health News:Immune Therapy May Help Some Heart Failure Patients 2Health News:Immune Therapy May Help Some Heart Failure Patients 3
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2VA Announces 2426 Million Construction Contract for Palo Alto 51841 1Vein Removal Method Linked to Bypass Results 51837 1Vein Removal Method Linked to Bypass Results 51837 2Vein Removal Method Linked to Bypass Results 51837 3Affordable Health Choices Act Is an Excellent Step Toward Health Care Reform 51832 1Affordable Health Choices Act Is an Excellent Step Toward Health Care Reform 51832 2